microbiome

Developing a range of products to modify the human
microbiome and bring specific health benefits

RNS & Investor News

Market launch for LPLDL® capsules in Germany

26 July 2017

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that HLH BioPharma Vertriebs GmbH ("HLH") have achieved product registration of LPLDL® capsules at IFA GmbH and "Bundesamt für Lebensmittelsicherheit und Verbraucherschutz (BVL)" and commenced commercial sales to pharmacies in Germany on 24 July 2017.

This announcement follows on from the three year supply agreement with HLH BioPharma Vertriebs GmbH ("HLH") announced on 15 June 2017. HLH will market capsules containing LPLDL® under the brand name Lactobact® LDL-Control and promote them directly to the pharmacy market in Germany, as well as to consumers on their online platform. Sales revenues are difficult to estimate in this new and developing market but are likely to be in the low to mid six figure in the near term growing as HLH builds market presence.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to see the first sales of our LPLDL® strain in products available to consumers in Germany. We hope this will be the first of many product launches of multiple formulations and presentations of LPLDL® as the active component in a wide range of pharmaceutical and consumer products around the world. HLH have an international reputation for providing high quality and scientifically validated products and are one of Europe's leading suppliers of probiotics to the pharmacy market. Establishing early sales of LPLDL® to pharmacies with HLH helps substantiate the credibility in the science behind LPLDL® to build the brand and acceptance in the larger consumer healthcare markets."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
   
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner
Tel: 020 7213 0880
   
finnCap (Broker)
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Tel: 020 7220 0500
   
Walbrook PR Ltd
Anna Dunphy
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

back to RNS & Investor News

 

Latest Tweets Twitter

top